News

In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...
As July concludes, momentum in lung cancer research continues to build, marked by FDA decisions, trial progress, and ...
Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how positive Phase III results for Emrelis may position AbbVie as a key player in MET-high non-small cell lung cancer, ...
EP: 3. Treatment Considerations for Patients With HER2+ NSCLC EP: 4. Latest Advances and Therapies for HER2+ NSCLC EP: 5. Unmet Needs and Clinical Considerations for HER2+ NSCLC EP: 6.
While chemotherapy remains a cornerstone of lung cancer treatment, it often weakens the immune system it relies on for ...
Session ID: 2025-04-19:b90ddef9bde8e2da8b1da91f Player Element ID: vjs_video_911 ...
Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...
Ivonescimab monotherapy vs. pembrolizumab as first-line (1L) treatment for PD-L1+ NSCLC Ivonescimab + chemotherapy vs. pembrolizumab + chemotherapy (global multicenter trial) as 1L treatment for NSCLC ...
The FDA approved Novocure medical device Optune Luna as a treatment for advanced cases of non-small cell lung cancer. The wearable technology delivers electrical fields that kill cancer cells.
Oral presentations also will highlight initial results from the TUXEDO-3 phase 2 trial (# 2005) evaluating patritumab deruxtecan in patients with metastatic breast cancer or advanced NSCLC and ...